此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Bundle Branch Pacing to Preserve Ejection Fraction in Atrial Fibrillation Trial (BEAT)

2026年8月6日 更新者:Poitiers University Hospital

Left Bundle Branch Area Pacing Versus Conventional Right Ventricular Pacing as Initial Strategy for Patients With Permanent Atrial Fibrillation and Preserved Left Ventricular Ejection Fraction Requiring Cardiac Pacing: an Open-label, Multicenter, Randomized Clinical Trial. - the BEAT Study -

The goal of this clinical trial is to learn whether left bundle branch area pacing, a technique designed to activate the heart's natural electrical conduction system, is better than conventional right ventricular pacing in adults with permanent atrial fibrillation, preserved heart pumping function, and a need for a pacemaker.

The main questions it aims to answer are:

Does left bundle branch area pacing reduce the risk of death, unplanned hospitalization for heart failure, or the need to replace the initial pacing system with biventricular pacing over 2 years? Does it better preserve heart function and quality of life, without increasing pacemaker-related complications?

Researchers will compare left bundle branch area pacing with conventional right ventricular pacing. A total of 642 participants will be randomly assigned to receive one of these two pacing strategies.

Participants will:

Have a single-chamber pacemaker implanted using either left bundle branch area pacing or conventional right ventricular pacing Undergo electrocardiograms, echocardiograms, and pacemaker checks during 2 years of follow-up Attend follow-up visits approximately 2, 12, and 24 months after implantation Be contacted by telephone approximately 6 and 18 months after implantation Complete questionnaires about their health and quality of life at the beginning and end of the study

研究概览

详细说明

The BEAT Study is a prospective, multicenter, open-label, randomized controlled clinical trial designed to compare left bundle branch area pacing with conventional right ventricular pacing as the initial pacing strategy in adults with permanent atrial fibrillation, preserved left ventricular ejection fraction, and an indication for permanent ventricular pacing.

Conventional right ventricular pacing is the standard pacing strategy for patients with bradycardia. The ventricular lead is usually positioned at the right ventricular apex or septum. Although this approach is well established, prolonged right ventricular pacing produces a non-physiological pattern of ventricular electrical activation. The resulting electrical and mechanical dyssynchrony may progressively impair left ventricular function and lead to pacing-induced cardiomyopathy, heart failure, hospitalization, and the need for a subsequent procedure to upgrade the pacing system to biventricular pacing.

Patients with permanent atrial fibrillation who require a pacemaker may be particularly exposed to these complications because they generally have a high burden of ventricular pacing. This applies both to patients with slow atrial fibrillation and to those undergoing atrioventricular node ablation for rapid atrial fibrillation. Although these patients may have preserved left ventricular systolic function at the time of pacemaker implantation, repeated non-physiological ventricular activation could contribute to subsequent deterioration in cardiac function.

Left bundle branch area pacing is a conduction-system pacing technique in which the ventricular lead is advanced through the interventricular septum to stimulate the left bundle branch or the surrounding conduction tissue. By recruiting the heart's intrinsic conduction system, this approach is intended to produce more physiological and synchronous ventricular activation than conventional right ventricular pacing. It may therefore preserve left ventricular function and reduce the clinical consequences associated with long-term ventricular pacing.

Evidence supporting left bundle branch area pacing has increased, particularly in patients with impaired left ventricular function or an indication for cardiac resynchronization. However, long-term randomized evidence remains limited in patients with permanent atrial fibrillation, preserved left ventricular ejection fraction, and an expected high ventricular pacing burden. In particular, the effect of the initial pacing strategy on major clinical events in this population has not been adequately established.

The study hypothesis is that left bundle branch area pacing, compared with conventional right ventricular pacing, will reduce clinically important adverse events over 2 years by limiting pacing-related ventricular dyssynchrony and preventing deterioration in left ventricular function.

A total of 642 participants will be enrolled and randomly assigned in a 1:1 ratio to one of two pacing strategies:

Left bundle branch area pacing: implantation of a single-chamber pacemaker with the ventricular lead positioned within the left bundle branch area through the interventricular septum to capture the cardiac conduction system.

Conventional right ventricular pacing: implantation of a single-chamber pacemaker with the ventricular lead positioned at the right ventricular apex or right ventricular septum.

Randomization will be stratified by participating center and by the indication for pacing: rapid permanent atrial fibrillation requiring atrioventricular node ablation or slow permanent atrial fibrillation. Because the implantation techniques are different and identifiable to the treating clinicians, the study is open label.

Participants will be followed for 24 months after pacemaker implantation. Study assessments will include clinical evaluation, pacemaker interrogation, 12-lead electrocardiography, echocardiography, collection of hospitalizations and cardiac reinterventions, assessment of adverse events, and evaluation of health-related quality of life. Follow-up will include clinical visits approximately 2, 12, and 24 months after implantation and telephone contacts approximately 6 and 18 months after implantation.

Echocardiography will be performed at baseline and at the end of the 2-year follow-up to evaluate changes in left ventricular systolic function and ventricular volumes. Pacemaker interrogation will be used to document device function and the proportion of ventricular pacing. Quality of life will be assessed using the Short Form-36 Health Survey and the Kansas City Cardiomyopathy Questionnaire.

The principal comparison will assess whether left bundle branch area pacing improves the proportion of participants who remain free from all-cause death, unplanned hospitalization for heart failure, and upgrade to biventricular pacing at 2 years. Additional analyses will examine cardiac function, individual clinical events, cardiac reinterventions, device- and procedure-related complications, and changes in quality of life. Unplanned heart failure hospitalizations and upgrades to biventricular pacing will be reviewed by an independent adjudication committee.

The primary analysis will follow the intention-to-treat principle. The study is intended to determine whether a physiological pacing strategy should replace conventional right ventricular pacing as the preferred initial approach for patients with permanent atrial fibrillation, preserved left ventricular function, and a substantial anticipated requirement for ventricular pacing.

研究类型

介入性

注册 (估计的)

642

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Age ≥ 18 years and <90 years
  • Atrial fibrillation requiring ventricular pacing because of

    1. rapid atrial fibrillation requiring atrioventricular node ablation; or
    2. slow atrial fibrillation i.e. ≤ 50 bpm on admission ECG).
  • Left ventricular ejection fraction ≥50%.
  • Affiliated person or beneficiary of the French social security scheme
  • Having given their informed consent.

Exclusion Criteria:

  • Indication for an implantable cardioverter defibrillator.
  • Presence of a mechanical tricuspid valve
  • Any prior attempt at implantation of an implantable cardioverter defibrillator, cardiac resynchronization therapy or LBBA pacing
  • Glomerular filtration rate <40 mL/min/1,73m2 with CKD-EPI formula
  • Chronic respiratory failure
  • Serious medical condition with life expectancy of <2 years
  • Pregnant or breastfeeding women, women of childbearing age who do not have effective contraception (hormonal/mechanical: per os, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy)
  • Persons benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergency situations

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:LBBA pacing
The LBBA pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted in the LBBA of the cardiac conduction system through the interventricular septum.
The LBBA pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted in the LBBA of the cardiac conduction system through the interventricular septum.
有源比较器:Conventional pacing
The conventional pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted either at the apex or the septum of the right ventricle.
The conventional pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted either at the apex or the septum of the right ventricle.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Proportion of post-implantation adverse events
大体时间:At two years
proportion of post-implantation adverse events, combining all-cause mortality, unplanned hospitalization related to heart failure, and upgrade to biventricular pacing.
At two years

次要结果测量

结果测量
措施说明
大体时间
Left ventricular ejection fraction
大体时间:At 2 years post-implantation.
Left ventricular ejection fraction assessed with echocardiography
At 2 years post-implantation.
Left ventricular end-systolic volume
大体时间:At 2 years post-implantation
Left ventricular end-systolic volume assessed with echocardiography
At 2 years post-implantation
Time to composite outcome
大体时间:Through study completion, an average of 2 years
Time to the first event between death, unplanned hospitalization related to heart failure, and upgrade to biventricular during the 2-year follow-up period
Through study completion, an average of 2 years
Unplanned hospitalization related to heart failure
大体时间:During the 2-year follow-up perio
Time to unplanned hospitalization for heart failure
During the 2-year follow-up perio
All-cause mortality
大体时间:During the 2-year follow-up period
Time to all-cause death
During the 2-year follow-up period
Upgrade to biventricular pacing
大体时间:During the 2-year follow-up period
Time to upgrade to biventricular
During the 2-year follow-up period
Complications
大体时间:During the 2-year follow-up period
Proportions of pocket hematoma, pneumothorax, lead dislodgment, pacing threshold elevation, pericardial effusion, pocket/wound infection, systemic infection, lead fracture, diaphragmatic stimulation, or pacemaker syndrome
During the 2-year follow-up period
Cardiac reintervention
大体时间:During the 2-year follow-up period
Time to cardiac reintervention for upgrade to biventricular pacing or due to a complication
During the 2-year follow-up period
Quality of life : Short Form 36 Questionnaire score
大体时间:Evolution between baseline and 2 years post-implantation
Evolution at the Short Form 36 Questionnaire score. Minimum score: 0; Maximum score: 100; A higher score indicates better health-related quality of life.
Evolution between baseline and 2 years post-implantation
Quality of life : Kansas City Cardiomyopathy Questionnaire score
大体时间:Evolution between baseline and 2 years post-implantation
Evolution at the Kansas City Cardiomyopathy Questionnaire score. Minimum: 0 - worst possible heart-failure-related health status; Maximum: 100 - best possible health status, with fewer symptoms and limitations
Evolution between baseline and 2 years post-implantation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月15日

初级完成 (估计的)

2028年8月14日

研究完成 (估计的)

2030年8月14日

研究注册日期

首次提交

2026年8月2日

首先提交符合 QC 标准的

2026年8月6日

首次发布 (实际的)

2026年8月12日

研究记录更新

最后更新发布 (实际的)

2026年8月12日

上次提交的符合 QC 标准的更新

2026年8月6日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅